摘要
目的探讨溶血磷脂酸(LPA)在上皮性卵巢癌诊断及病情监测中的价值。方法选择2005年4月至10月河北医科大学第四医院收治的40例初治上皮性卵巢癌患者,测定其术前和术后的血浆LPA和CA125,同时测定其中20例腹水中的LPA,并选择同期20例良性卵巢肿瘤患者血浆和腹腔冲洗液作对照。结果上皮性卵巢癌组术前血浆LPA明显高于良性对照组(P<0·01),且术后水平低于术前(P<0·01)。上皮性卵巢癌患者腹水LPA明显高于良性卵巢肿瘤患者腹腔冲洗液(P<0·01)。LPA诊断Ⅰ期上皮性卵巢癌的敏感性及特异性分别是75%和80%。CA125的敏感性及特异性分别是25%和40%。结论LPA升高可能成为早期上皮性卵巢癌诊断的新的生物学指标,同时可监测病情并判断病人的预后。
Objective To investigate the value of lysophosphatidic acid for diagnosis and monitoring of ovarian epithelial cancer. Methods We measured LPA and CA125 in plasma and in ascitic fluid from ovarian epithelial cancer（ n = 40） with preoperative and postoperative and benign ovarian neoplasm （n = 20） from 2005-04 to 2OO5-10 in the Fourth Hospital of Hebei Medical University. Results Patients with ovarian epithelial cancer had significantly higher plasma and ascitic fluid LPA levels compared with the benign control group（P 〈0. 01 P 〈0. 01 ） ,and postoperative LPA levels were significantly lower than preoperative levels（P 〈0. 01 ）. The diagnostic sensitivity and specificity of plasma LPA for stage I ovarian epithelial cancer were 75% and 80% ,while CA125 was 50% and 40%. Conclusion LPA levels may be a new biomarker for detecting early-stage ovarian epithelial cancer. LPA levels appear useful as monitoring and prognostic biomarkers of ovarian epithelial cancer.
出处
《中国实用妇科与产科杂志》
CAS
CSCD
北大核心
2007年第8期599-601,共3页
Chinese Journal of Practical Gynecology and Obstetrics
